{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Itacitinib&page=2", "query": { "intervention": "Itacitinib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Itacitinib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T12:27:53.229Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02760485", "title": "A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "itacitinib", "type": "DRUG" }, { "name": "ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2016-12-29", "completion_date": "2022-06-06", "has_results": true, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-09-24T12:27:53.229Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Duarte, California • Long Beach, California + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02760485" }, { "nct_id": "NCT03425006", "title": "Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2018-06-18", "completion_date": "2021-10-11", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-09-24T12:27:53.229Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03425006" }, { "nct_id": "NCT05823571", "title": "Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Acute", "Myelodysplastic Syndromes", "Myelomonocytic Leukemia, Chronic", "T-cell Prolymphocytic Leukemia", "CML", "Myeloproliferative Disorders", "Multiple Myeloma", "Plasma Cell Leukemia" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 32, "start_date": "2023-07-06", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2025-09-18", "last_synced_at": "2026-09-24T12:27:53.229Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05823571" }, { "nct_id": "NCT02559492", "title": "Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "INCB050465", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2015-11", "completion_date": "2019-08-18", "has_results": false, "last_update_posted_date": "2019-09-25", "last_synced_at": "2026-09-24T12:27:53.229Z", "location_count": 11, "location_summary": "Duarte, California • Denver, Colorado • New Haven, Connecticut + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02559492" }, { "nct_id": "NCT01626573", "title": "A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Itacitinib Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 106, "start_date": "2012-03", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2019-03-12", "last_synced_at": "2026-09-24T12:27:53.229Z", "location_count": 17, "location_summary": "Palm Desert, California • Pasadena, California • Lake Mary, Florida + 14 more", "locations": [ { "city": "Palm Desert", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Ocala", "state": "Florida" }, { "city": "Palm Harbor", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01626573" }, { "nct_id": "NCT03144687", "title": "A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MPN (Myeloproliferative Neoplasms)" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2018-01-26", "completion_date": "2021-06-01", "has_results": true, "last_update_posted_date": "2022-06-16", "last_synced_at": "2026-09-24T12:27:53.229Z", "location_count": 19, "location_summary": "Tempe, Arizona • Orange, California • Aurora, Colorado + 16 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03144687" }, { "nct_id": "NCT04339101", "title": "Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia", "Hematologic and Lymphocytic Disorder", "Myelodysplastic Syndrome", "Primary Myelofibrosis", "Secondary Myelofibrosis" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Itacitinib Adipate", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 59, "start_date": "2020-11-11", "completion_date": "2025-10-09", "has_results": true, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-09-24T12:27:53.229Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04339101" }, { "nct_id": "NCT03584516", "title": "GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Chronic Graft-versus-host Disease" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2019-01-17", "completion_date": "2023-11-03", "has_results": true, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-09-24T12:27:53.229Z", "location_count": 39, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03584516" }, { "nct_id": "NCT03272464", "title": "INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Trametinib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "INCB039110", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2019-05-29", "completion_date": "2019-12-27", "has_results": true, "last_update_posted_date": "2023-09-22", "last_synced_at": "2026-09-24T12:27:53.229Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03272464" }, { "nct_id": "NCT05757219", "title": "Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Chimeric antigen receptor (CAR) T-cell therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2023-05-19", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-24T12:27:53.229Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05757219" } ] }